CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $850,400 | +4713.8% | 47,192 | +4190.2% | 0.01% | – |
| Q1 2023 | $17,666 | -53.5% | 1,100 | -42.9% | 0.00% | – |
| Q3 2022 | $38,000 | -75.9% | 1,925 | -77.3% | 0.00% | -100.0% |
| Q2 2022 | $158,000 | +45.0% | 8,478 | +70.4% | 0.00% | 0.0% |
| Q1 2022 | $109,000 | +137.0% | 4,975 | +205.8% | 0.00% | – |
| Q4 2021 | $46,000 | -89.6% | 1,627 | -92.2% | 0.00% | -100.0% |
| Q3 2021 | $441,000 | +90.9% | 20,938 | +70.5% | 0.01% | +100.0% |
| Q2 2021 | $231,000 | – | 12,281 | +72141.2% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 17 | -98.5% | 0.00% | – |
| Q4 2020 | $16,000 | -38.5% | 1,168 | -21.2% | 0.00% | – |
| Q2 2020 | $26,000 | -78.0% | 1,483 | -68.4% | 0.00% | -100.0% |
| Q4 2019 | $118,000 | +337.0% | 4,700 | +164.3% | 0.00% | +100.0% |
| Q3 2019 | $27,000 | – | 1,778 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |